Investigating the effects of cangrelor in patients undergoing heart procedures
PharmacOdynaMic Effects of Cangrelor in PatiEnts wIth Acute or chronIc Coronary Syndrome Undergoing Percutaneous Coronary Intervention (POMPEII Registry)
Federico II University · NCT04790032
This study is testing how well a drug called cangrelor works to reduce blood clotting in patients having heart procedures to see if it helps them better than other treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Federico II University (other) |
| Locations | 1 site (Napoli) |
| Trial ID | NCT04790032 on ClinicalTrials.gov |
What this trial studies
This prospective registry aims to explore the pharmacodynamic effects of cangrelor in patients undergoing percutaneous coronary intervention (PCI). The study will collect blood samples and perform platelet function tests using advanced methods to assess the drug's impact on platelet reactivity. By focusing on patients with acute and chronic coronary syndromes, the research seeks to identify rates and predictors of high residual platelet reactivity (HRPR) when treated with cangrelor. The study will be conducted at the University Hospital of Naples Federico II, where investigators will gather clinical and demographic data alongside pharmacodynamic measurements.
Who should consider this trial
Good fit: Ideal candidates for this study are adult patients undergoing PCI who will receive cangrelor.
Not a fit: Patients who do not consent to blood or data collection will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of cangrelor's effectiveness, leading to improved treatment strategies for patients undergoing PCI.
How similar studies have performed: While there is significant interest in cangrelor's effects, this study aims to fill a gap in pharmacodynamic data, making it a novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All adult patients undergoing PCI and receiving cangrelor administration will be eligible for inclusion in the study. Exclusion Criteria: * only those not providing consent to blood/data collection will be excluded.
Where this trial is running
Napoli
- University Federico II of Naples — Napoli, Italy (RECRUITING)
Study contacts
- Principal investigator: Giuseppe Gargiulo, MD, PhD — Department of Advanced Biomedical Sciences, University Federico II of Naples, Italy
- Study coordinator: Giuseppe Gargiulo, MD, PhD
- Email: giuseppe.gargiulo1@unina.it
- Phone: +39-0817463075
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Percutaneous Coronary Intervention, Cangrelor, Acute coronary syndrome, Chronic coronary syndrome